FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3095734189> ?p ?o ?g. }

• W3095734189 endingPage "50" @default.
• W3095734189 startingPage "49" @default.
• W3095734189 abstract "Introduction: Asciminib is a new BCR-ABL1 inhibitor that differs from previous tyrosine kinase inhibitors (TKIs) in that it does not bind to the ATP-binding site of the kinase. Data from different clinical trials has shown an adequate safety and efficacy profile in chronic myeloid leukemia (CML) patients failing previous TKIs. However, no findings have been communicated in real life experience. The aim of our study is to present first results of asciminib in CML patients failing previous TKIs under the current compassionate use program. Methods: We retrospectively collected data from 31 patients treated with asciminib in 25 centers under compassionate use program. Data collecting was performed between October 2018 and June 2020. Patients baseline characteristics are shown in table 1. Most patients were heavily pretreated with 28 patients receiving 3 or more TKIs previous to asciminib. Eleven patients (35.5%) had been treated with ponatinib at some point throughout the disease. Twelve patients showed BCR-ABL1 mutations (only 1 case with T315I mutation). Switch to asciminib was due to intolerance in 22 patients and due to resistance in the remaining 9. Median dose of asciminib was 80mg per day (40mg every 12 hours). Treatment responses were evaluated according to European Leukemia Net recommendations. Data compilation and analysis were performed with REDCap Software and IBM SPSS (Version 25.0). Results: Median time on asciminib for the entire cohort was 35 weeks. Regarding toxicities, 13 patients (42%) experienced mild extra-hematological side effects (grade 1-2) being the most frequent fatigue (19%), joint pain (16%) and nausea (9%). Four patients (12,9%) showed severe (grade 3-4) extra-hematological events: fatigue, hepatotoxicity, hypertension and pericardial effusion (1 patient each). Three patients (9,7%) suffered from grade 4 thrombocytopenia, 2 of them associating grade 4 neutropenia. All toxicities according to previous TKIs adverse effects as well as cross-intolerance data is shown in table 2. Dose reduction had to be carried out in 9 patients (29%), 7 of those with temporary treatment interruptions; most owing to hematological adverse effects. In terms of efficacy (Graph 1), probability of reaching or at least maintaining previous response was 100%, 61.3% and 35.5% for complete hematological response (CHR), complete cytogenetic response (CCyR) and major molecular response (MMR), respectively. Regarding probabilities to improve previous responses, rates of CCyR and MMR were, respectively, 22,2% (2/9) and 22,2% (2/9) for resistant patients and 44% (4/9) and 62,5%. (10/16) for intolerant group. Amid the 11 patients previously treated with ponatinib, 3 patients (27,3%) showed improvement of response achieving at least MMR, 2 of them from the TKI-intolerant group and 1 from the TKI-resistant group. The median follow-up time was 40 weeks, after which 27 patients (87.1%) continued with asciminib. Treatment cessation happened in 2 patients due to progression to blastic phase and in 2 patients due to lack of efficacy. No patients discontinued due to side effects. Conclusion: The data presented, similar to that known from clinical trials, supports the use of asciminib in routine clinical practice in CML patients failing to previous TKIs. Disclosures Garcia-Gutiérrez: Novartis: Consultancy, Other: Travel, Accommodation, Expenses, Research Funding; Bristol-Myers Squibb: Consultancy, Other: Travel, Accommodation, Expenses, Research Funding; Pfizer: Consultancy, Other: Travel, Accommodation, Expenses, Research Funding; Incyte: Consultancy, Other: Travel, Accommodation, Expenses, Research Funding." @default.
• W3095734189 created "2020-11-09" @default.
• W3095734189 creator A5000389588 @default.
• W3095734189 creator A5000552138 @default.
• W3095734189 creator A5005632772 @default.
• W3095734189 creator A5015795278 @default.
• W3095734189 creator A5016332912 @default.
• W3095734189 creator A5018381223 @default.
• W3095734189 creator A5021246278 @default.
• W3095734189 creator A5022516664 @default.
• W3095734189 creator A5029438721 @default.
• W3095734189 creator A5030407146 @default.
• W3095734189 creator A5032618701 @default.
• W3095734189 creator A5034287486 @default.
• W3095734189 creator A5036922520 @default.
• W3095734189 creator A5037662864 @default.
• W3095734189 creator A5038339460 @default.
• W3095734189 creator A5038339678 @default.
• W3095734189 creator A5041905085 @default.
• W3095734189 creator A5042934235 @default.
• W3095734189 creator A5050546153 @default.
• W3095734189 creator A5054581056 @default.
• W3095734189 creator A5058883576 @default.
• W3095734189 creator A5060111541 @default.
• W3095734189 creator A5060840797 @default.
• W3095734189 creator A5061812273 @default.
• W3095734189 creator A5062808218 @default.
• W3095734189 creator A5063332826 @default.
• W3095734189 creator A5067159029 @default.
• W3095734189 creator A5073093146 @default.
• W3095734189 creator A5074268126 @default.
• W3095734189 creator A5080522770 @default.
• W3095734189 creator A5083438110 @default.
• W3095734189 creator A5086280000 @default.
• W3095734189 date "2020-11-05" @default.
• W3095734189 modified "2023-10-18" @default.
• W3095734189 title "Safety and Efficacy Profile of Asciminib As Treatment in Chronic Myeloid Leukemia Patients after Several Tyrosine-Kinase Inhibitors Failure" @default.
• W3095734189 doi "https://doi.org/10.1182/blood-2020-138690" @default.
• W3095734189 hasPublicationYear "2020" @default.
• W3095734189 type Work @default.
• W3095734189 sameAs 3095734189 @default.
• W3095734189 citedByCount "2" @default.
• W3095734189 countsByYear W30957341892021 @default.
• W3095734189 countsByYear W30957341892023 @default.
• W3095734189 crossrefType "journal-article" @default.
• W3095734189 hasAuthorship W3095734189A5000389588 @default.
• W3095734189 hasAuthorship W3095734189A5000552138 @default.
• W3095734189 hasAuthorship W3095734189A5005632772 @default.
• W3095734189 hasAuthorship W3095734189A5015795278 @default.
• W3095734189 hasAuthorship W3095734189A5016332912 @default.
• W3095734189 hasAuthorship W3095734189A5018381223 @default.
• W3095734189 hasAuthorship W3095734189A5021246278 @default.
• W3095734189 hasAuthorship W3095734189A5022516664 @default.
• W3095734189 hasAuthorship W3095734189A5029438721 @default.
• W3095734189 hasAuthorship W3095734189A5030407146 @default.
• W3095734189 hasAuthorship W3095734189A5032618701 @default.
• W3095734189 hasAuthorship W3095734189A5034287486 @default.
• W3095734189 hasAuthorship W3095734189A5036922520 @default.
• W3095734189 hasAuthorship W3095734189A5037662864 @default.
• W3095734189 hasAuthorship W3095734189A5038339460 @default.
• W3095734189 hasAuthorship W3095734189A5038339678 @default.
• W3095734189 hasAuthorship W3095734189A5041905085 @default.
• W3095734189 hasAuthorship W3095734189A5042934235 @default.
• W3095734189 hasAuthorship W3095734189A5050546153 @default.
• W3095734189 hasAuthorship W3095734189A5054581056 @default.
• W3095734189 hasAuthorship W3095734189A5058883576 @default.
• W3095734189 hasAuthorship W3095734189A5060111541 @default.
• W3095734189 hasAuthorship W3095734189A5060840797 @default.
• W3095734189 hasAuthorship W3095734189A5061812273 @default.
• W3095734189 hasAuthorship W3095734189A5062808218 @default.
• W3095734189 hasAuthorship W3095734189A5063332826 @default.
• W3095734189 hasAuthorship W3095734189A5067159029 @default.
• W3095734189 hasAuthorship W3095734189A5073093146 @default.
• W3095734189 hasAuthorship W3095734189A5074268126 @default.
• W3095734189 hasAuthorship W3095734189A5080522770 @default.
• W3095734189 hasAuthorship W3095734189A5083438110 @default.
• W3095734189 hasAuthorship W3095734189A5086280000 @default.
• W3095734189 hasBestOaLocation W30957341891 @default.
• W3095734189 hasConcept C10515644 @default.
• W3095734189 hasConcept C126322002 @default.
• W3095734189 hasConcept C143998085 @default.
• W3095734189 hasConcept C2777413986 @default.
• W3095734189 hasConcept C2777583451 @default.
• W3095734189 hasConcept C2778729363 @default.
• W3095734189 hasConcept C2780381907 @default.
• W3095734189 hasConcept C2909065710 @default.
• W3095734189 hasConcept C3019892230 @default.
• W3095734189 hasConcept C535046627 @default.
• W3095734189 hasConcept C66339696 @default.
• W3095734189 hasConcept C71924100 @default.
• W3095734189 hasConcept C72563966 @default.
• W3095734189 hasConceptScore W3095734189C10515644 @default.
• W3095734189 hasConceptScore W3095734189C126322002 @default.
• W3095734189 hasConceptScore W3095734189C143998085 @default.
• W3095734189 hasConceptScore W3095734189C2777413986 @default.
• W3095734189 hasConceptScore W3095734189C2777583451 @default.
• W3095734189 hasConceptScore W3095734189C2778729363 @default.
• W3095734189 hasConceptScore W3095734189C2780381907 @default.

• next